SLC5A2 and intestinal disorder: Future studies are warranted specifically in GSD Ib since the introduction of SGLT2 inhibitors (such as empagliflozin) for treatment in GSD Ib has resulted in decreased inflammatory bowel disease and intestinal disease [18–20].